Meaghan Elliott

Meaghan Elliott is an experienced professional in clinical operations with a significant tenure at Alnylam Pharmaceuticals, where roles have included Associate Director, Senior Manager, and Clinical Operations Manager since April 2019. Prior experience includes positions at Stealth BioTherapeutics as Senior Clinical Trial Manager and Clinical Trial Manager, and BIND Therapeutics as Senior Clinical Trial Associate. Meaghan has also served as a member of the Board of Trustees for Myrtle Street Condominium Association since February 2017. Meaghan's background encompasses a transition from regulatory operations to clinical trial management, with extensive responsibilities in overseeing clinical studies, ensuring GCP compliance, and collaborating on global clinical strategies. Educational credentials include a Bachelor of Science in Biology from the University of Massachusetts Amherst, along with prior roles in the fitness industry and as an allocation analyst.